TELA Bio (TELA) Scheduled to Post Quarterly Earnings on Thursday

TELA Bio (NASDAQ:TELA) will be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. TELA Bio has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

TELA Bio (NASDAQ:TELA) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The business had revenue of $17.00 million during the quarter, compared to the consensus estimate of $16.65 million. TELA Bio had a negative return on equity of 201.62% and a negative net margin of 79.83%. On average, analysts expect TELA Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Price Performance

Shares of TELA opened at $4.59 on Tuesday. The firm’s 50-day simple moving average is $5.36 and its two-hundred day simple moving average is $5.89. TELA Bio has a fifty-two week low of $4.23 and a fifty-two week high of $11.26. The stock has a market cap of $113.14 million, a PE ratio of -2.22 and a beta of 1.00. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.45 and a current ratio of 4.23.

Analyst Ratings Changes

Several research analysts have recently issued reports on TELA shares. Piper Sandler dropped their target price on shares of TELA Bio from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, March 22nd. JMP Securities restated a “market outperform” rating and issued a $15.00 price target on shares of TELA Bio in a research note on Friday, March 22nd.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.